Sign in
Active, not recruitingNo phase

Myopia Control With a Innovative Spectacle Lens - A Cessation Study

Key facts

Who runs it
Essilor International
Where
Boston, Chicago, New York, Pittsburg, and Vestal, United StatesSee the 5 sites
Trial code
Status
Active, not recruiting
People taking part
91 people enrolled
Started
18 Feb 2025
Expected to end
Nov 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Single Vision Lens to A innovative spectacle lens
Record updated
11 September 2026

Who can take part

Age
9 years to 15 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (4)Hide the full registry criteria

Who can take part

  • Existing subjects from the NCT05174780 clinical study
  • Ability to comply with study procedures
  • Informed consent of parent/guardian and assent of subject

Who cannot take part

  • Current ocular infection, inflammation, or irritation likely to affect vision

Where in United States

  • New England College of OptometryBoston, United States
  • Illinois College of OptometryChicago, United States
  • SUNY College of OptometryNew York, United States
  • Kannarr Eye CarePittsburg, United States
  • Sacco Eye GroupVestal, United States

About the trial

What the trial wants to find out

The purpose of this study is to quantify myopic progression following cessation of a innovative spectacle lenses after 3 years' use.

The 2 groups in the trial

  • (Previous Test Group) - Single Vision Spectacle Lens - Innovative LensTreatment being tested

    Treatment: Single Vision Lens to A innovative spectacle lens

  • (Previous Control Group) - Single Vision Spectacle Lens - Innovative LensPlacebo, for comparison

    Treatment: Single Vision Lens to A innovative spectacle lens

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Evaluation of A Innovative Spectacle Lens in Slowing Myopia Progression - A Cessation Study
Record updated
11 September 2026